CDC ENTEBBE

A vaccine, BNT116 by BioNTech, targeting non-small cell lung cancer (NSCLC) is being tested in Maryland and Virginia, aiming to eliminate cancer cells and prevent recurrence through a global clinical trial. Using mRNA technology, it trains the immune system to recognize and attack NSCLC-specific tumor markers. The trial, recruiting participants in the D.C. region, will test BNT116's efficacy alone and with chemotherapy/immunotherapy, aiming to prevent lung cancer recurrence.

Intensive dietary interventions, including intermittent energy restriction (IER) and continuous energy restriction (CER), were effective in reducing BMI z scores and BMI percentiles in obese adolescents with metabolic complications, without significant differences in body composition or cardiometabolic outcomes between IER and CER groups.

Pfizer and BioNTech receive FDA approval for Omicron KP.2-adapted COVID-19 vaccine for individuals 12 years and older, with emergency use authorization for those 6 months through 11 years. The vaccine is based on mRNA technology and will be available in pharmacies, hospitals, and clinics across the U.S.

Tecovirimat did not improve clade I mpox resolution in DRC, but showed safe use and lower mortality. Ongoing trials like PALM007 and STOMP aim to develop effective mpox interventions.

Mount Sinai team created a dataset and POND dashboard using NHANES data to personalize interventions for youth prediabetes and diabetes, identifying 27 risk-associated variables.